UNIVERSITY OF WASHINGTON MED CTR
- Type
- Teaching hospital
- Where
- Seattle, WA
- Medicare CCN
- 500008
- Received
- $42,233,457 in 2,178 records, 2019 ($4,119,254 general, $38,114,202 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 430 | $4,119,254 |
| 2019 | Research payment | 1,748 | $38,114,202 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,748 | $38,114,202 |
| Grant | 89 | $1,440,893 |
| Royalty or License | 60 | $568,458 |
| Education | 48 | $566,639 |
| Consulting Fee | 47 | $534,723 |
| Space rental or facility fees (teaching hospital only) | 97 | $475,697 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 57 | $453,956 |
| Charitable Contribution | 3 | $26,000 |
| Honoraria | 9 | $23,591 |
| Gift | 13 | $14,305 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 5 | $14,000 |
| Food and Beverage | 1 | $926 |
| Travel and Lodging | 1 | $63 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Intuitive Surgical, Inc. | $52,320 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Medtronic USA, Inc. | $36,511 | Research payment | In-kind items and services | StealthStation Device, Image Guided Surgery Products | Investigator Sponsored Research | 2019 |
| 2019-12-31 | Allergan, Inc. | $34,607 | Research payment | Cash or cash equivalent | AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of | 2019 | |
| 2019-12-31 | Allergan, Inc. | $34,607 | Research payment | Cash or cash equivalent | AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of | 2019 | |
| 2019-12-31 | Philips North America LLC | $26,880 | Research payment | Cash or cash equivalent | Ingenia CX 3 0T Device, Devices | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $10,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $9,708 | Research payment | In-kind items and services | A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or with | 2019 | |
| 2019-12-31 | Stryker Corporation | $6,923 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Insulet Corporation | $6,315 | Research payment | In-kind items and services | Omnipod Device, Insulin Pump | Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 | 2019 |
| 2019-12-31 | Stryker Corporation | $4,492 | Gift | In-kind items and services | NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Roche Diagnostics Corporation | $2,017 | Education | In-kind items and services | MD cobas Instruments and Reagents Device, Molecular Diagnostics | 2019 | |
| 2019-12-31 | Acerta Pharma LLC | $1,813 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2019 |
| 2019-12-31 | Roche Diagnostics Corporation | $1,672 | Education | In-kind items and services | MD cobas Instruments and Reagents Device, Molecular Diagnostics | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,659 | Research payment | In-kind items and services | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum Resistant Ovaria | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $1,631 | Research payment | Cash or cash equivalent | UW2017MRIPR8471061MossaBasha | 2019 | |
| 2019-12-31 | Linvatec Corporation | $1,337 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $938 | Research payment | Cash or cash equivalent | UWashIPR10162016MossaBasha | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $871 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $680 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | Forxiga HF-D1699C00001 HF rEF Outcome study | 2019 |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $641 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $480 | Research payment | Cash or cash equivalent | UWash2019MRIPR1047MossaBasha | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $346 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2019 | |
| 2019-12-31 | Acerta Pharma LLC | $194 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Proof of Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed or Refractory BCe | 2019 |
| 2019-12-31 | Allergan, Inc. | $59 | Research payment | Cash or cash equivalent | A PHASE 2B DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEDI2070 IN SUBJECT | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $17 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $55,700 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, Oncology | A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma | 2019 |
| 2019-12-30 | PFIZER INC. | $38,522 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2019 |
| 2019-12-27 | Janssen Research & Development, LLC | $4,102 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2019 | |
| 2019-12-27 | Regeneron Pharmaceuticals, Inc. | $2,393 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RE | 2019 |
| 2019-12-26 | PFIZER INC. | $337,840 | Research payment | In-kind items and services | MYLOTARG Biological, ONCOLOGY | PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF GEMTUZUMAB OZOGAMICINMYLOTARG IN COMBINATION WITH CYTARABINE AN | 2019 |
| 2019-12-26 | Janssen Research & Development, LLC | $20,841 | Research payment | Cash or cash equivalent | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction | 2019 | |
| 2019-12-26 | Gen-Probe, Inc. | $7,090 | Research payment | Cash or cash equivalent | Panther Device, Diagnostics | P10934-CMVPS-CSP-01 | 2019 |
| 2019-12-24 | Amgen Inc. | $70,000 | Research payment | Cash or cash equivalent | Hepatic transport mechanisms of conjugated metabolites of sex steroids | 2019 | |
| 2019-12-24 | ABIOMED | $9,840 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | CVAD REGISTRY | 2019 |
| 2019-12-24 | Amgen Inc. | $9,494 | Research payment | Cash or cash equivalent | AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. | 2019 | |
| 2019-12-24 | Amgen Inc. | $2,325 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-12-24 | Amgen Inc. | $1,044 | Research payment | Cash or cash equivalent | Blincyto Biological, Oncology | Adult R/R ALL Registry - Serial Chart Review | 2019 |
| 2019-12-23 | Janssen Research & Development, LLC | $40,075 | Research payment | Cash or cash equivalent | ZYTIGA Drug, Oncology | 2019 | |
| 2019-12-23 | Janssen Research & Development, LLC | $28,514 | Research payment | Cash or cash equivalent | A Phase 2 Study of ARN-509 in Active Surveillance Patients | 2019 | |
| 2019-12-23 | Novo Nordisk Inc | $24,136 | Research payment | Cash or cash equivalent | Tresiba Drug, Diabetes | A randomized parallel comparison of BRidging to Insulin Degludec using insulin GlarginE versus direc | 2019 |
| 2019-12-23 | Janssen Research & Development, LLC | $19,760 | Research payment | Cash or cash equivalent | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction | 2019 | |
| 2019-12-23 | Edwards Lifesciences Corporation | $19,296 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-23 | Edwards Lifesciences Corporation | $19,296 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-23 | Janssen Research & Development, LLC | $7,701 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-23 | Edwards Lifesciences Corporation | $4,605 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-23 | Bayer Healthcare Pharmaceuticals Inc. | $3,758 | Research payment | Cash or cash equivalent | Stivarga Drug, Oncology | BAY73-4506 phase I HCC 1st line combination PD1inh | 2019 |
| 2019-12-23 | Edwards Lifesciences Corporation | $3,125 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-23 | Edwards Lifesciences Corporation | $2,540 | Research payment | Cash or cash equivalent | Trial 2017-18 ExCEED | 2019 | |
| 2019-12-20 | Gilead Sciences, Inc. | $70,000 | Research payment | Cash or cash equivalent | Optimizing HCV Treatment for Kenyan Persons Who Inject Drugs to Achieve Micro-Elimination | 2019 | |
| 2019-12-20 | Shionogi Inc | $37,213 | Research payment | Cash or cash equivalent | Fetroja Drug, Infections and Infectious Diseases | Assessment of the In Vivo Efficacy of Cefiderocol against Gram-Negative Bacteria under iron-depleted and iron-overloaded | 2019 |
| 2019-12-20 | Edwards Lifesciences Corporation | $19,296 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-20 | ABBVIE INC. | $11,341 | Research payment | Cash or cash equivalent | M14-239 | 2019 | |
| 2019-12-20 | Abbott Laboratories | $5,080 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-20 | Edwards Lifesciences Corporation | $4,397 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-20 | Zimmer Biomet Holdings, Inc. | $434 | Gift | In-kind items and services | SS Small Distal Tib Device, Foot & Ankle | 2019 | |
| 2019-12-19 | PFIZER INC. | $38,522 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2019 |
| 2019-12-19 | SANOFI PASTEUR INC. | $22,543 | Research payment | Cash or cash equivalent | HSV VACCINE Drug | HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurre | 2019 |
| 2019-12-19 | ABBVIE INC. | $14,042 | Research payment | Cash or cash equivalent | M18-918 | 2019 | |
| 2019-12-19 | Celgene Corporation | $9,486 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-19 | Janssen Research & Development, LLC | $9,408 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-19 | Abbott Laboratories | $6,831 | Consulting Fee | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | 2019 | |
| 2019-12-19 | Canon Medical Systems USA, Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, Multiple | 2019 | |
| 2019-12-19 | Novartis Pharmaceuticals Corporation | $4,267 | Research payment | Cash or cash equivalent | CFZ533A Drug | A PARTIALLY-BLINDED, ACTIVE-CONTROLLED, MULTICENTER, RANDOMIZED STUDY EVALUATING EFFICACY, SAFETY, TOLERABILITY, PHARMAC | 2019 |
| 2019-12-19 | Intercept Pharmaceuticals, Inc. | $3,321 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-19 | Agios Pharmaceuticals, Inc. | $2,781 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY | 2019 |
| 2019-12-19 | Halozyme Inc | $1,900 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-19 | ROCHE MOLECULAR SYSTEMS, INC. | $855 | Research payment | Cash or cash equivalent | COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics | RD003901 | 2019 |
| 2019-12-19 | Intercept Pharmaceuticals, Inc. | $571 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-19 | Becton, Dickinson and Company | $500 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-18 | PFIZER INC. | $371,102 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-18 | Edwards Lifesciences Corporation | $64,410 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-18 | SEAGEN INC. | $11,902 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2019 | |
| 2019-12-18 | Gilead Sciences, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-18 | Gilead Sciences, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-18 | SEAGEN INC. | $1,060 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2019 | |
| 2019-12-18 | PFIZER INC. | $707 | Research payment | Cash or cash equivalent | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRAC | 2019 | |
| 2019-12-17 | PFIZER INC. | $57,783 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2019 |
| 2019-12-17 | SANOFI PASTEUR INC. | $37,554 | Research payment | Cash or cash equivalent | HSV VACCINE Drug | HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurre | 2019 |
| 2019-12-17 | Becton, Dickinson and Company | $21,416 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-17 | Allergan, Inc. | $12,382 | Research payment | Cash or cash equivalent | AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of | 2019 | |
| 2019-12-17 | Boston Scientific Corporation | $9,497 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2019 | |
| 2019-12-17 | BIOTRONIK INC. | $8,890 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2019 | |
| 2019-12-17 | Allergan, Inc. | $6,054 | Research payment | Cash or cash equivalent | AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of | 2019 | |
| 2019-12-17 | ARRAY BIOPHARMA INC | $4,052 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-17 | Medical Device Business Services, Inc. | $2,976 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-17 | Becton, Dickinson and Company | $1,349 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-17 | Becton, Dickinson and Company | $1,218 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-17 | Becton, Dickinson and Company | $54 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-17 | Becton, Dickinson and Company | $20 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-17 | Becton, Dickinson and Company | $8 | Royalty or License | Cash or cash equivalent | BD PHARMINGEN Device, CELL ANALYSIS | 2019 | |
| 2019-12-16 | Dynavax Technologies Corporation | $87,186 | Research payment | Cash or cash equivalent | DV281 Drug | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | 2019 |
| 2019-12-16 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-12-16 | Janssen Research & Development, LLC | $25,000 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-12-16 | Sebela Pharmaceuticals Inc. | $14,750 | Research payment | Cash or cash equivalent | A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrau | 2019 | |
| 2019-12-16 | Dynavax Technologies Corporation | $10,684 | Research payment | Cash or cash equivalent | DV281 Drug | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | 2019 |
| 2019-12-16 | Dynavax Technologies Corporation | $9,404 | Research payment | Cash or cash equivalent | DV281 Drug | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | 2019 |
| 2019-12-16 | Dynavax Technologies Corporation | $3,300 | Research payment | Cash or cash equivalent | DV281 Drug | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | 2019 |
| 2019-12-16 | Dynavax Technologies Corporation | $1,206 | Research payment | Cash or cash equivalent | DV281 Drug | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $527 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE III | 2019 |
| 2019-12-15 | Genentech, Inc. | $120,000 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRE-CLINCAL12152019 | 2019 |
| 2019-12-13 | Genentech, Inc. | $575,000 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | MULLER GLIA REPROGRAMMING TO PHOTORECEPTORS | 2019 |
| 2019-12-13 | Edwards Lifesciences Corporation | $12,072 | Research payment | Cash or cash equivalent | Early-TAVR Trial 2016-07 | 2019 | |
| 2019-12-13 | Medtronic Vascular, Inc. | $3,841 | Research payment | Cash or cash equivalent | PERIGON | 2019 | |
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | AstraZeneca Pharmaceuticals LP | $2,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-12 | Alnylam Pharmaceuticals Inc. | $10,660 | Research payment | Cash or cash equivalent | GIVLARRI Drug, Genetic Disease | ENVISION A Study to Evaluate the Efficacy and Safety of Givosiran ALN-AS1 in Patients With Acute Hepatic Porphyrias AHP | 2019 |
| 2019-12-12 | Ferring International Pharmascience Center US | $10,321 | Research payment | Cash or cash equivalent | DEGARELIX Drug, UROLOGY | A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Ev | 2019 |
| 2019-12-12 | Gen-Probe, Inc. | $9,782 | Research payment | Cash or cash equivalent | Mycoplasma genitalium Device, Diagnostics | Mycoplasma genitalium surveillance project | 2019 |
| 2019-12-12 | Halozyme Inc | $5,545 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-12 | Genentech, Inc. | $4,421 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | BTK FIH P1A | 2019 |
| 2019-12-12 | Genentech, Inc. | $2,163 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ATEZOLIZUMAB IN MUSCLE INVASIVE BLADDER CANCER MIBC | 2019 |
| 2019-12-11 | PFIZER INC. | $25,137 | Research payment | In-kind items and services | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $2,731 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-11 | Shire North American Group Inc | $1,653 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-12-11 | Shire North American Group Inc | $1,653 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-12-11 | Shire North American Group Inc | $1,653 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $1,425 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-11 | EMD Serono, Inc. | $1,155 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-001 | 2019 |
| 2019-12-11 | Shire North American Group Inc | $991 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-12-10 | PFIZER INC. | $57,783 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2019 |
| 2019-12-10 | PFIZER INC. | $56,565 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2019 |
| 2019-12-10 | Incyte Corporation | $21,625 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2019 | |
| 2019-12-10 | Edwards Lifesciences Corporation | $12,282 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-10 | Exelixis Inc. | $6,667 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib XL184 vs Placebo in Subjects With Hepatocellular C | 2019 |
| 2019-12-10 | PFIZER INC. | $3,672 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2019 |
| 2019-12-10 | ABBVIE INC. | $2,322 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-10 | ABBVIE INC. | $930 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-10 | ABBVIE INC. | $790 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-10 | Agios Pharmaceuticals, Inc. | $445 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY | 2019 |
| 2019-12-10 | ABBVIE INC. | $317 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-10 | Eli Lilly and Company | $285 | Research payment | Cash or cash equivalent | CYRAMZA Drug, Oncology | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXE | 2019 |
| 2019-12-10 | ABBVIE INC. | $254 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-10 | ABBVIE INC. | $247 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-10 | ABBVIE INC. | $240 | Research payment | Cash or cash equivalent | M13-813 | 2019 | |
| 2019-12-09 | PFIZER INC. | $34,645 | Research payment | In-kind items and services | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRAC | 2019 | |
| 2019-12-09 | Janssen Research & Development, LLC | $30,448 | Research payment | Cash or cash equivalent | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction | 2019 | |
| 2019-12-09 | SANOFI US SERVICES INC. | $18,050 | Research payment | Cash or cash equivalent | SAR439859 Drug | A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered O | 2019 |
| 2019-12-09 | Janssen Research & Development, LLC | $7,931 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2019 | |
| 2019-12-09 | SANOFI US SERVICES INC. | $6,972 | Research payment | Cash or cash equivalent | SOTAGLIFLOZIN Drug | A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy | 2019 |
| 2019-12-09 | Bayer Healthcare Pharmaceuticals Inc. | $3,924 | Research payment | Cash or cash equivalent | Stivarga Drug, Oncology | BAY73-4506 phase I HCC 1st line combination PD1inh | 2019 |
| 2019-12-09 | VENTANA MEDICAL SYSTEMS, INC. | $3,569 | Research payment | In-kind items and services | DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics | RD002198 | 2019 |
| 2019-12-09 | SANOFI US SERVICES INC. | $1,862 | Research payment | Cash or cash equivalent | SAR439859 Drug | A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered O | 2019 |
| 2019-12-09 | Novo Nordisk Inc | $1,454 | Research payment | In-kind items and services | Tresiba Drug, Diabetes | A randomized parallel comparison of BRidging to Insulin Degludec using insulin GlarginE versus direc | 2019 |
| 2019-12-09 | Incyte Corporation | $190 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Incyte Corporation | $94 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Incyte Corporation | $91 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Incyte Corporation | $60 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Novo Nordisk Inc | $49 | Research payment | In-kind items and services | A randomized parallel comparison of BRidging to Insulin Degludec using insulin GlarginE versus direc | 2019 | |
| 2019-12-09 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Incyte Corporation | $9 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-09 | Incyte Corporation | $6 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-12-07 | Halozyme Inc | $1,828 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-07 | Halozyme Inc | $1,677 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-07 | Genentech, Inc. | $678 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | IMMOTION 151 APDL1 IN RENAL CELL CARCINOMA RCC | 2019 |
| 2019-12-07 | Halozyme Inc | $98 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-07 | Halozyme Inc | $63 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-07 | Halozyme Inc | $63 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-06 | Carl Zeiss Meditec, Inc. | $50,000 | Research payment | Cash or cash equivalent | CIRRUS HD-OCT Device, Optical Tomographer | 2019 | |
| 2019-12-06 | Regeneron Pharmaceuticals, Inc. | $36,680 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-12-06 | Genentech, Inc. | $6,925 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2019 |
| 2019-12-05 | TESARO, Inc. | $17,915 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE | 2019 |
| 2019-12-05 | PFIZER INC. | $14,011 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF LORLATINIB PF06463922 MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRSTLINE | 2019 |
| 2019-12-05 | PFIZER INC. | $8,858 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF LORLATINIB PF06463922 MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRSTLINE | 2019 |
| 2019-12-05 | ROCHE MOLECULAR SYSTEMS, INC. | $6,776 | Research payment | Cash or cash equivalent | COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics | RD003901 | 2019 |
| 2019-12-05 | PFIZER INC. | $6,250 | Research payment | Cash or cash equivalent | A PHASE 1 OPENLABEL DOSE ESCALATION STUDY OF PF04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF05082566 IN PATIENTS | 2019 | |
| 2019-12-05 | PFIZER INC. | $5,190 | Research payment | Cash or cash equivalent | A PHASE 1 OPENLABEL DOSE ESCALATION STUDY OF PF04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF05082566 IN PATIENTS | 2019 | |
| 2019-12-05 | Halozyme Inc | $2,603 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-05 | Philips North America LLC | $2,500 | Grant | Cash or cash equivalent | GlideLight Device, Devices | 2019 | |
| 2019-12-05 | Intercept Pharmaceuticals, Inc. | $2,378 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-05 | Genentech, Inc. | $940 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | IMMOTION 151 APDL1 IN RENAL CELL CARCINOMA RCC | 2019 |
| 2019-12-05 | PFIZER INC. | $342 | Research payment | Cash or cash equivalent | A PHASE 1 OPENLABEL DOSE ESCALATION STUDY OF PF04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF05082566 IN PATIENTS | 2019 | |
| 2019-12-04 | PFIZER INC. | $9,203 | Research payment | Cash or cash equivalent | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRAC | 2019 | |
| 2019-12-04 | Gilead Sciences, Inc. | $7,364 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976 | 2019 | |
| 2019-12-04 | Gilead Sciences, Inc. | $3,270 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-96 | 2019 | |
| 2019-12-04 | Edwards Lifesciences Corporation | $581 | Research payment | Cash or cash equivalent | PARTNER II 2010-12 | 2019 | |
| 2019-12-04 | Richard-Allan Scientific Llc | $74 | Royalty or License | Cash or cash equivalent | 2019 | ||
| 2019-12-03 | EMD Serono, Inc. | $131,440 | Research payment | Cash or cash equivalent | Bavencio Biological, Oncology | EMR 100070-003 | 2019 |
| 2019-12-03 | Clovis Oncology, Inc. | $8,412 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-12-03 | PFIZER INC. | $8,398 | Research payment | Cash or cash equivalent | FIP STUDY FOR PRMT5 | 2019 | |
| 2019-12-03 | PFIZER INC. | $4,856 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2019 |
| 2019-12-03 | ABBVIE INC. | $1,821 | Research payment | Cash or cash equivalent | Venclexta Drug, Virology | M15-654 | 2019 |
| 2019-12-02 | SEAGEN INC. | $153,240 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A phase III study of brentuximab vedotin, ifosfamide I, carboplatin C, and etoposide E, for relapsed or refractory Hodgk | 2019 |
| 2019-12-02 | SANOFI US SERVICES INC. | $32,624 | Research payment | Cash or cash equivalent | SAR439859 Drug | A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered O | 2019 |
| 2019-12-02 | Agios Pharmaceuticals, Inc. | $26,289 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-12-02 | PFIZER INC. | $25,137 | Research payment | In-kind items and services | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2019 |
| 2019-12-02 | PFIZER INC. | $13,680 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2019 |
| 2019-12-02 | Janssen Research & Development, LLC | $11,341 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-02 | Janssen Research & Development, LLC | $6,814 | Consulting Fee | Cash or cash equivalent | SIMPONI Biological, Immunology | 2019 | |
| 2019-12-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | An Open Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma CITADEL | 2019 | |
| 2019-11-30 | Mallinckrodt Enterprises LLC | $5,383 | Research payment | Cash or cash equivalent | A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUB | 2019 | |
| 2019-11-30 | Roche Diagnostics Corporation | $2,017 | Education | In-kind items and services | MD cobas Instruments and Reagents Device, Molecular Diagnostics | 2019 | |
| 2019-11-30 | Roche Diagnostics Corporation | $1,672 | Education | In-kind items and services | MD cobas Instruments and Reagents Device, Molecular Diagnostics | 2019 | |
| 2019-11-29 | Genentech, Inc. | $32,705 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH IB PERSONALIZED CANCER VACCINE ATEZOLIZUMABB | 2019 |
| 2019-11-29 | Janssen Research & Development, LLC | $10,191 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 |
The latest 200 records of 2,178.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Seattle, WA, county King County, WA, state Washington; placed by its city name.
| Measure | Place (city or town) Seattle, WA | County King County, WA | State Washington |
|---|---|---|---|
| Population B01003 | 754,195 | 2,287,171 | 7,816,116 |
| Population, 2020 census P1 | 737,015 | 2,269,675 | 7,705,281 |
| Median age B01002 | 35.6 | 37.4 | 38.3 |
| Under 18 B01001 | 13.8% | 19.5% | 21.4% |
| 65 and over B01001 | 13.0% | 14.0% | 16.6% |
| Households B11001 | 363,466 | 941,054 | 3,064,820 |
| Foreign born B05002 | 20.2% | 25.8% | 15.4% |
| Median household income B19013 | $123,860 | $124,746 | $98,141 |
| Median family income B19113 | $188,938 | $160,840 | $118,075 |
| Per capita income B19301 | $86,095 | $74,100 | $53,744 |
| Poverty rate B17001 | 9.9% | 8.6% | 9.9% |
| Unemployment rate B23025 | 4.6% | 4.8% | 5.1% |
| Civilian labor force B23025 | 489,320 | 1,320,458 | 4,024,423 |
| Mean commute (minutes) B08013 | 26.0 | 27.6 | 26.6 |
| Bachelor's degree or higher B15003 | 68.4% | 56.7% | 39.6% |
| Housing units B25001 | 393,918 | 1,003,284 | 3,306,620 |
| Owner-occupied B25003 | 43.7% | 55.4% | 63.8% |
| Renters B25003 | 56.3% | 44.6% | 36.2% |
| Median home value B25077 | $938,600 | $859,900 | $564,600 |
| Median gross rent B25064 | $2,030 | $2,092 | $1,760 |
| White, not Hispanic B03002 | 58.8% | 52.9% | 63.1% |
| Black B03002 | 6.4% | 6.4% | 3.8% |
| Hispanic or Latino B03002 | 8.5% | 11.0% | 14.4% |
| Asian B03002 | 17.5% | 20.5% | 9.7% |
| American Indian and Alaska Native B03002 | 0.3% | 0.4% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Seattle, WA.
Comments